Adjusted relative risks reduced for non-COVID-19 mortality after receipt of Pfizer-BioNTech, Moderna, Janssen vaccines
MONDAY, Oct. 25, 2021 (HealthDay News) — COVID-19 vaccine recipients do not have an increased risk for non-COVID-19 mortality, according to research published in the Oct. 22 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Stanley Xu, Ph.D., from Kaiser Permanente Southern California in Pasadena, and colleagues examined mortality not associated with COVID-19 after COVID-19 vaccination in a general population setting. The study was conducted among about 11 million persons from seven Vaccine Safety Datalink (VSD) sites during December 2020 to July 2021.
The researchers found that COVID-19 vaccine recipients had lower non-COVD-19 mortality than unvaccinated persons after standardizing mortality rates by age and sex. The adjusted relative risk (aRR) of non-COVID-19 mortality for the Pfizer-BioNTech vaccine was 0.41 and 0.34 after doses 1 and 2, respectively, after adjustment for demographic characteristics and VSD site. For the Moderna vaccine, the aRRs were 0.34 and 0.31 after doses 1 and 2, respectively. After receipt of the Janssen vaccine, the aRR was 0.54.
“There is no increased risk for mortality among COVID-19 vaccine recipients,” the authors write. “This finding reinforces the safety profile of currently approved COVID-19 vaccines in the United States.”
Several authors disclosed financial ties to the biopharmaceutical industry.
Copyright © 2021 HealthDay. All rights reserved.
